Cancer BiologyOncogenePeer-reviewed
ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to PARP inhibition in lung cancer
T. Moreno, L. Gonzalez-Silva, B. Monterde…·I. Varela
This study identifies ARID2 deficiency in 20% of lung cancer patients, showing it promotes tumor progression and increases sensitivity to PARP inhibition.
DOI 10.1038/s41388-021-01748-y